Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 281

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

MicroRNA-145 Targeted Therapy Reduces Atherosclerosis

Open access
Lovren, Fina, Pan, Yi, Quan, Adrian, Singh, Krishna K., Shukla, Praphulla C., Gupta, Nandini, Steer, Brent M., Ingram, Alistair J., Gupta, Milan, Al-Omran, Mohammed, Teoh, Hwee, Marsden, Philip A., Verma, Subodh·2012·Circulation

Abstract

Background—: MicroRNA are essential posttranscriptional modulators of gene expression implicated in various chronic diseases. Because microRNA-145 is highly expressed in vascular smooth muscle cells (VSMC) and regulates VSMC fate and plasticity, we hypothesized that it may be a novel regulator of atherosclerosis and plaque stability. Methods and Results—: Apolipoprotein E knockout mice ( ApoE −/− ) mice were treated with either a microRNA-145 lentivirus under the control of the smooth muscle cell (SMC)-specific promoter SM22 α or a SM22 α control lentivirus before commencing the Western diet for 12 weeks. The SMC-targeted microRNA-145 treatment markedly reduced plaque size in aortic sinuses, ascending aortas, and brachiocephalic arteries. It also significantly increased fibrous cap area, reduced necrotic core area, and increased plaque collagen content. Cellular plaque composition analyses revealed significantly less macrophages in ApoE −/− mice treated with the SMC-specific microRNA-145. These mice also demonstrated marked increases in calponin levels and α-smooth muscle actin–positive SMC areas in their atherosclerotic lesions. Furthermore, lentiviral delivery of microRNA-145 resulted in reduced KLF4 and elevated myocardin expression in aortas from ApoE −/− mice, consistent with an effect of microRNA-145 to promote a contractile phenotype in VSMC. Conclusions—: VSMC-specific overexpression of microRNA-145 is a novel in vivo therapeutic target to limit atherosclerotic plaque morphology and cellular composition, shifting the balance toward plaque stability vs plaque rupture.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.084186

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 281

Metadata

Authors
Lovren, F., Pan, Y., Quan, A., Singh, K. K., Shukla, P. C., Gupta, N., Steer, B. M., Ingram, A. J., Gupta, M., Al-Omran, M., Teoh, H., Marsden, P. A., & Verma, S.
Venue
Circulation
Published
2012-09-11
Volume
126
Issue
11_suppl_1
Pages
S81-90
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2094644076
Cited by
281
References
34
FWCI
6.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MicroRNA-145 Targeted Therapy Reduces Atherosclerosis. https://app.cochat.ai/papers/10.1161/circulationaha.111.084186
The paper
Lovren, F., Pan, Y., Quan, A., Singh, K. K., Shukla, P. C., Gupta, N., Steer, B. M., Ingram, A. J., Gupta, M., Al-Omran, M., Teoh, H., Marsden, P. A., & Verma, S. (2012). MicroRNA-145 Targeted Therapy Reduces Atherosclerosis. Circulation. https://doi.org/10.1161/circulationaha.111.084186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.